Skip to main content
Glama

Findymail

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description adds significant behavioral context beyond annotations: it details data sources (SEC EDGAR/XBRL for companies, FAERS for drugs), fiscal year handling, sorting by primary metric, and return of citation URIs. Annotations already indicate read-only, idempotent, non-destructive, and open-world, and the description aligns well.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is comprehensive but slightly verbose; however, every sentence adds value. It is well-structured with example queries up front. Could be marginally tighter, but overall efficient.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema, the description adequately describes the return format (paired data + citation URIs, sorted by primary metric). It covers both entity types and mentions edge cases (off-calendar fiscal years). No critical gaps are apparent.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although the input schema covers both parameters (100% coverage), the description enriches understanding by explaining what data each entity type pulls (financials vs. adverse events), specifying the format for values (tickers/CIKs for company, names for drug), and enforcing bounds (2-5 items). This goes beyond schema descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool performs side-by-side comparisons of 2-5 companies or drugs, citing specific query examples like 'compare X and Y' and 'which is bigger'. It distinguishes itself from sequential single-pack lookups, making its purpose distinct from sibling tools.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly states when to use this tool (comparisons, ranking, head-to-head) and when to prefer it over alternatives, saying 'ALWAYS PREFER over sequential single-pack lookups'. It effectively guides the agent to choose this tool over sequential single-entity lookups.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation2/5

Several tools have heavily overlapping purposes: ask_pipeworx and ask_pipeworx_beta are currently identical, deep_research/validate_claim/ask_pipeworx all route factual questions to the same underlying catalog, and ai_visibility_check is essentially wrapped by scan_competitor_ai_presence. The long descriptions help, but the boundaries between query, research, and verification tools are genuinely ambiguous.

Naming Consistency2/5

Names are all lowercase snake_case, but there is no consistent verb_noun or domain pattern: ask_pipeworx, findymail_find_email, scan_competitor_ai_presence, polymarket_kalshi_spread, and generate_llms_txt each use a different structural convention. The mix of brand prefixes, domain prefixes, and bare commands makes the naming feel ad hoc rather than systematic.

Tool Count2/5

33 tools is well over the 25+ threshold and reflects a server that bundles at least five distinct concerns: email lookup, structured data research, prediction-market analysis, subscriptions, and memory. Most individual tools earn their place, but the count is too high for coherent tool selection in a single MCP server.

Completeness3/5

Coverage is broad and mostly self-sufficient for the Pipeworx data ecosystem: querying, deep research, entity resolution, comparisons, verification, subscriptions, memory, and one-off utilities are all present. There are notable gaps though—there is no tool to fetch a full record from a returned pipeworx:// citation URI, and the Findymail side is limited to find/reverse with no verification or bulk capability.